RWJ-394,674
From Wikipedia, the free encyclopedia
|
RWJ-394,674
|
|
| Systematic (IUPAC) name | |
| N,N-diethyl-4-((8-phenethyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl)benzamide | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C33H38N2O |
| Mol. mass | 478.667 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
Legal |
| Routes | ? |
RWJ-394,674 is a drug which is used in scientific research. It is a potent, orally active analgesic drug, which produces little respiratory depression. RWJ-394,674 itself is a potent and selective agonist for δ-opioid receptors, with a Ki of 0.24nM at δ and 72nM at μ. However once inside the body, RWJ-394,674 is dealkylated to its monodesethyl metabolite RWJ-413,216 which is a potent agonist at the μ-opioid receptor and has less affinity for δ (Ki 0.26nM at μ, 46.7nM at δ). The effect of RWJ-394,674 when administered in vivo thus produces potent agonist effects at both μ and δ receptors through the combined actions of the parent drug and its active metabolite, with the δ-agonist effects counteracting the respiratory depression from the μ-opioid effects, and the only prominent side effect being sedation.[1]
[edit] References
- ^ Codd EE, Carson JR, Colburn RW, Dax SL, Desai-Krieger D, Martinez RP, McKown LA, Neilson LA, Pitis PM, Stahle PL, Stone DJ, Streeter AJ, Wu WN, Zhang SP. The novel, orally active, delta opioid RWJ-394674 is biotransformed to the potent mu opioid RWJ-413216. Journal of Pharmacology and Experimental Therapeutic. 2006 Sep;318(3):1273-9. PMID 16766719

